2. LDL Established Target for Cardiovascular Risk

3. PCSK9 Mechanism of Action

4. Genetics PCSK9

5. PCSK9 Loss-of-function Mutations

6. PCSK9-Directed Therapies in Development

8. PCSK9 Monoclonal Antibodies

9. MENDEL Evolocumab Monotherapy for Hypercholesterolemia Study Design

10. MENDEL

11. MENDEL-2

12. ODYSSEY MONO Arilocumab Monotherapy for Hypercholesterolemia

13. PCSK9 Monoclonal Antibodies

14. PCSK9 Inhibition in Patients With Hypercholesterolemia Receiving Statin Therapy

15. Alirocumab on Top of Atorvastatin in Primary Hypercholesterolemia

16. LAPLACE-2 LDL-C Response at Mean of Weeks 10 and 12

17. PCSK9 Monoclonal Antibodies

18. GAUSS-1 Phase 2 Evolocumab in Statin-Intolerant Patients

19. GAUSS-1 % Change in LDL-C From Baseline at Week 12

20. GAUSS-2 Study Design Phase 3 Efficacy and Safety Study of Evolocumab in Statin-Intolerant Patients

21. GAUSS-2 % Change in LDL-C From Baseline at Week 12

22. PCSK9 Monoclonal Antibodies

23. Effect of Alirocumab on LDL-C in Heterozygous FH

24. RUTHERFORD Effect of Evolocumab on LDL-C in Heterozygous FH

25. RUTHERFORD-2

26. TESLA Trial Evaluating Evolocumab in Homozygous FH

27. PCSK9 Monoclonal Antibodies

28. DESCARTES Percentage Change in LDL-C From Baseline at Week 52 in Patients With Hypercholesterolemia

29. DESCARTES Evolocumab Safety at 52 weeks

30. OSLER Phase 3 Extension Study

31. OSLER Effect of Evolocumab on LDL-C after 52 Weeks

32. Alirocumab Trials ODYSSEY FH I and FH II Studies

33. FH I and FH II Results Over 52 Weeks

34. ODYSSEY Combo II Study

35. Combo II Results Over 52 Weeks

36. FH I, FH II, Combo II AEs Occurring in ≥ 5% of Patients

37. ODYSSEY Long-term Study Design

38. ODYSSEY Long-term Study LDL-C Reduction

39. ODYSSEY Long-term Study AEs

40. ODYSSEY Long-term Study* CV Death

41. OSLER Phase 3 Extension Study

42. OSLER Effect of Evolocumab on LDL-C after 52 Weeks

43. PCSK9 CV Outcomes Trials

44. Abbreviations

45. Abbreviations (cont)

46. Abbreviations (cont)

47. References

48. References (cont)

49. References (cont)

50. References (cont)

51. References (cont)

52. References (cont)

53. References (cont)